This content is machine translated Update 2025 Hypercholesterolemia The past 18 months have noticeably shifted the LDL-lowering landscape: An ESC/EAS-Focused Update 2025 sharpens the indication thresholds, real-world data confirm the benefit of early combinations after myocardial infarction, bempedoic...…
View Post 9 min This content is machine translated Venous thromboembolism prevention PCSK9 inhibitors: Current evidence, mechanisms and unanswered questions Venous thromboembolism (VTE), consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cause of cardiovascular mortality worldwide after myocardial infarction and stroke. Despite continuous...…
View Post 5 min This content is machine translated Metabolic Dysfunction-Associated Steatotic Liver Disease Cardiology and hepatology in one boat Metabolic dysfunction has far-reaching negative effects on the body, which can manifest as cardiovascular and liver disease. Traditionally, these conditions have been treated in an organ-centered manner, resulting in isolated…
View Post 3 min This content is machine translated Blood pressure and lipid management Effects of effective therapy on cardiovascular health. A major factor in the development of atherosclerotic-related cardiovascular disease is the retention and accumulation of cholesterol-rich lipoproteins in the vessels. Therefore, in addition to adequate blood pressure control, the…
View Post 4 min This content is machine translated Interview on the ACC/AHA guidelines Lipid treatment recommendation meets with little approval Statins continue to be the drug of choice for LDL-C therapy, although not all patients achieve their target levels with therapy alone. However, the paradigm shift implemented in the new…
